Patient Medication Guide: How many courses of ixazomib are needed to treat myeloma?

Ixazomib is an oral proteasome inhibitor commonly used to treat multiple myeloma. The specific number and duration of treatment courses will vary depending on individual circumstances and will be determined by the doctor based on the patient's condition and treatment response. Typically, treatment with ixazomib is administered continuously, with each course usually lasting four weeks. Before treatment begins, the doctor will assess the patient's overall health and use this information to determine an appropriate treatment plan.

Treatment with ixazomib was more effective in delaying the progression of multiple myeloma than placebo in clinical studies based on the time to first progression of multiple myeloma. Time to first progression was extended to 20.6 months in the ixazomib group, 21.4 months in patients with high-risk cytogenetics, 18.4 months in stage III patients, and 18.5 months in patients over 75 years old. Overall, treatment with ixazomib usually requires multiple courses to achieve optimal therapeutic effects. The specific number of sessions will vary depending on the patient's clinical manifestations and response to treatment.

The original drug of Ixazomib has been launched in China and is included in Class B medical insurance. The price of common capsule preparations may be more than 10,000 yuan per box, which is relatively expensive. The price of the original drug of ixazomib sold overseas is more than 10,000 US dollars per box (the price may fluctuate due to the exchange rate). Ixazomib Generic drugs are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 4mg*3 tablets produced by a Laos pharmaceutical factory may be less than 1,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.